Other languages Mendus AB

Equities

IMMU

SE0005003654

Delayed Nasdaq Stockholm Other stock markets 07:11:42 2024-04-25 am EDT			5-day change	1st Jan Change
0.4765 ^SEK	-2.76%		-6.39%	-8.89%

Apr. 16	Mendus AB Announces Board Changes	CI
Mar. 27	Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mendus AB Announces Board Changes	Apr. 16
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	Mar. 27
Mendus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13
Mendus AB Announces Clinical Pipeline Update	Dec. 22
Mendus AB Appoints Ted Fjällman as Board Member	Dec. 13
Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023	Dec. 11
Mendus AB and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML	Dec. 06
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting	Nov. 17
Mendus AB Presents Updated Alison Clinical Trial Data for Vididencel in Ovarian Cancer At SITC 2023	Nov. 06
Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal	Nov. 03
Mendus AB Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data	Nov. 02
Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23	23-09-21
Mendus Obtains US FDA's Fast Track Tag for Blood Cancer Therapy	23-09-08
Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia	23-09-08
Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29
Mendus AB Announces the Publication of Novel Preclinical Data on its Intratumoral Priming Strategy in the Peer-Reviewed Medical Journal 'Frontiers in Immunology	23-08-16
Mendus AB Appoints Lewis Lanier to Scientific Advisory Board	23-06-20
Sweden’s Mendus Receives European Medicines Agency Certification for Cancer Vaccine	23-06-19
Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023	23-06-12
Eurozone's Q1 Recession Weigh on Most EU Markets Thursday	23-06-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mendus AB

Equities

IMMU

SE0005003654

Other languages

Filters